Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  04:03 2022-10-04 pm EDT
44.46 USD   +0.72%
01:18aModerna asks Japan health ministry to approve BA.5-tailored vaccine
AQ
10/04Health Care Up on Growth Optimism -- Health Care Roundup
DJ
10/04Sector Update: Health Care Stocks Advance Premarket Tuesday
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Major test of first possible Lyme vaccine in 20 years begins

08/08/2022 | 04:46pm EDT

DUNCANSVILLE, Pa. (AP) — Researchers are seeking thousands of volunteers in the U.S. and Europe to test the first potential vaccine against Lyme disease in 20 years -- in hopes of better fighting the tick-borne threat.

Lyme is a growing problem, with cases rising and warming weather helping ticks expand their habitat. While a vaccine for dogs has long been available, the only Lyme vaccine for humans was pulled off the U.S. market in 2002 from lack of demand, leaving people to rely on bug spray and tick checks.

Now Pfizer and French biotech Valneva are aiming to avoid previous pitfalls in developing a new vaccine to protect both adults and kids as young as 5 from the most common Lyme strains on two continents.

“There wasn’t such a recognition, I think, of the severity of Lyme disease" and how many people it affects the last time around, Pfizer vaccine chief Annaliesa Anderson told The Associated Press.

Robert Terwilliger, an avid hunter and hiker, was first in line Friday when the study opened in central Pennsylvania. He’s seen lots of friends get Lyme and is tired of wondering if his next tick bite will make him sick.

“It’s always a worry, you know? Especially when you’re sitting in a tree stand hunting and you feel something crawling on you,” said Terwilliger, 60, of Williamsburg, Pennsylvania. “You’ve got to be very, very cautious.”

Exactly how often Lyme disease strikes isn't clear. The Centers for Disease Control and Prevention cites insurance records suggesting 476,000 people are treated for Lyme in the U.S. each year. Pfizer’s Anderson put Europe’s yearly infections at about 130,000.

Black-legged ticks, also called deer ticks, carry Lyme-causing bacteria. The infection initially causes fatigue, fever and joint pain. Often -- but not always -- the first sign is a red, round bull's-eye rash.

Early antibiotic treatment is crucial, but it can be hard for people to tell if they were bitten by ticks, some as small as a pin. Untreated Lyme can cause severe arthritis and damage the heart and nervous system. Some people have lingering symptoms even after treatment.

Most vaccines against other diseases work after people are exposed to a germ. The Lyme vaccine offers a different strategy — working a step earlier to block a tick bite from transmitting the infection, said Dr. Gary Wormser, a Lyme expert at New York Medical College who isn’t involved with the new research.

How? It targets an “outer surface protein” of the Lyme bacterium called OspA that’s present in the tick’s gut. It’s estimated a tick must feed on someone for about 36 hours before the bacteria spreads to its victim. That delay gives time for antibodies the tick ingests from a vaccinated person’s blood to attack the germs right at the source.

In small, early-stage studies, Pfizer and Valneva reported no safety problems and a good immune response. The newest study will test if the vaccine, called VLA15, really protects and is safe. The companies aim to recruit at least 6,000 people in Lyme-prone areas including the Northeast U.S. plus Finland, Germany, the Netherlands, Poland and Sweden.

They’ll receive three shots, either the vaccine or a placebo, between now and next spring’s tick season. A year later, they’ll get a single booster dose.

“We’re really looking at something that’s a seasonal vaccine,” Anderson said, so people have high antibody levels during the months when ticks are most active.

Volunteers can be as young as 5 and should be at high risk because they spend a lot of time in tick-infested areas, such as hikers, campers and hunters, said Dr. Alan Kivitz who heads one of the study sites at Altoona Center for Clinical Research in Duncansville, Pennsylvania.

In his own practice, “not a single day goes by that someone either has a concern about Lyme disease, could possibly have Lyme disease,” Kivitz said.

This new candidate is different from a previous Lyme vaccine that GlaxoSmithKline pulled off the market in 2002 amid controversy and low sales. With about 75% effectiveness, that old Lyme shot got a lukewarm endorsement from vaccine experts, wasn't tested in children and drew unsubstantiated reports of joint-related side effects.

While the new Pfizer-Valneva vaccine also targets the OspA protein, it's engineered somewhat differently than its predecessor and also targets six Lyme strains in the U.S. and Europe instead of just one.

The Pfizer study will span two tick seasons to get answers — but it's not the only research into new ways to prevent Lyme. University of Massachusetts scientists are working on a vaccine alternative, shots of pre-made Lyme-fighting antibodies.

And Yale University researchers are in early stages of designing a vaccine that recognizes a tick's saliva — which in animal testing sparked a skin reaction that made it harder for ticks to hang on and feed.

Since different tick species carry many diseases other than Lyme, ultimately “we're all hoping for a tick-bite prevention vaccine,” Wormser said.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Copyright 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News

Stocks mentioned in the article
ChangeLast1st jan.
PFIZER, INC. 0.72% 44.46 Delayed Quote.-24.71%
VALNEVA SE 0.10% 5.762 Real-time Quote.-76.49%
All news about PFIZER, INC.
01:18aModerna asks Japan health ministry to approve BA.5-tailored vaccine
AQ
10/04Health Care Up on Growth Optimism -- Health Care Roundup
DJ
10/04Sector Update: Health Care Stocks Advance Premarket Tuesday
MT
10/04Voyager Therapeutics Says Pfizer to License Adeno-Associated Virus Capsid Targeting Rar..
MT
10/04Pfizer Says Phase 3 Study of Talzenna Combined With Xtandi Meets Primary Endpoint in Me..
MT
10/04Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial
BU
10/04Voyager Therapeutics : Pfizer Exercises One of Two Capsid Options
DJ
10/04Pfizer's Prostate Cancer Drug Trial Meets Key Target
DJ
10/03Pfizer Closes $11.6 Billion Biohaven Pharmaceutical Buyout
MT
10/03Pfizer Completes Acquisition of Biohaven Pharmaceuticals
BU
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 102 B - -
Net income 2022 32 739 M - -
Net cash 2022 10 262 M - -
P/E ratio 2022 7,85x
Yield 2022 3,64%
Capitalization 250 B 250 B -
EV / Sales 2022 2,36x
EV / Sales 2023 2,93x
Nbr of Employees 79 000
Free-Float 59,0%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 44,46 $
Average target price 55,75 $
Spread / Average Target 25,4%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-24.71%249 525
JOHNSON & JOHNSON-3.19%435 445
ELI LILLY AND COMPANY16.41%313 453
ROCHE HOLDING AG-12.23%279 092
ABBVIE INC.4.87%251 052
NOVO NORDISK A/S6.91%238 512